Document is current
Any future updates will be listed below
-
Authors
Trewin-Nybråten, Cassia Bree https://orcid.org/0000-0001-8236-9423
Lambert, Paul Christopher https://orcid.org/0000-0002-5337-663X
Marienhagen, Kirsten
Andreassen, Lasse
Johannesen, Tom Børge https://orcid.org/0000-0001-8633-1633
Niehusmann, Pitt https://orcid.org/0000-0002-3247-5241
Oltedal, Leif https://orcid.org/0000-0003-3316-7950
Schipmann, Stephanie https://orcid.org/0000-0002-9971-2256
Skjulsvik, Anne Jarstein https://orcid.org/0000-0003-0287-4628
Solheim, Ole https://orcid.org/0000-0002-5954-4817
Solheim, Tora Skeidsvoll https://orcid.org/0000-0002-2565-8437
Sundstrøm, Terje https://orcid.org/0000-0002-6503-7141
Vik-Mo, Einar Osland https://orcid.org/0000-0001-8303-4123
Brandal, Petter https://orcid.org/0000-0003-0259-495X
Ingebrigtsen, Tor https://orcid.org/0000-0001-5966-9786
Skaga, Erlend https://orcid.org/0000-0003-3942-3492
,
Bjerkvig, Rolf
Miletic, Hrvoje
Larsson, Ine Marie
Våg, Ingeborg
Dørum, Liv Marit
-
Funding
Funding for this research was provided by:
UiT The Arctic University of Norway
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 18 August 2025
First Online: 11 September 2025
Declarations
:
: The authors CBT, PCL, KM, LA, TBJ, AJS, OS and TSS have no conflicts of interest to declare that are relevant to the content of this article.
: LO has received research support from the West Norway Regional Health Authority (ID13426, ID37828). SS has received consulting fees for NX Development. TS has received support for travel for attending meetings with the advisory board for the Norwegian Brain and Spinal Cord Tumour Registry. EOVM has received research support from the Norwegian Cancer Society, the Research Council of Norway, the South-Eastern Norway Regional Health Authority and TRANSCAN. EOVM is an invited lecturer in a symposium organized by Oxford Nanopore Technologies. PB has received research support from the Norwegian Cancer Society and the South-Eastern Norway Regional Health Authority. PB has received consulting fees for Ekspertpanelet (national institution) and Moloklinikken. ES has received research support (paid to institution) from the Research Fund Foundation of Oslo University Hospital and the South-Eastern Norway Regional Health Authority.
: LO is the leader of the Global ECT-MRI Research collaboration (GEMRIC). SS is a board member of ALA-RDT in GBM, ALA SDT Glioma 401. PB is the leader of the Norwegian Neuro-Oncology Group and board leader of the Norwegian Oncological Forum. TI is the leader of the advisory board for the Norwegian Brain and Spinal Cord Tumour Registry. TI is an executive board member of the Norwegian Cancer Society and the Norwegian Neurosurgical Society.
: The analyses presented in this study are covered by the purview of the Cancer Registry of Norway’s mandate and approval to provide delivery of tailored statistics.
: Informed consent from the subjects was not required according to the Norwegian Health Register Act § 19.
